New Immunomodulatory Therapy Strategies in Chronic Reactive Arthritis
Summary
1. to investigate, whether one of the two alternative therapy strategies (antibiotic plus immunostimulation versus antibiotic plus immunosuppression) in chronic reactive arthritis is therapeutical superior to conventionel standardtherapy (DMARD). 2. to investigate, whether one or more of the different therapy strategies cause an altered detection of bacterial DNA in the joint or colon. 3. to measure the antigen-specific and -unspecific immune response (predominantly t-cell response) during therapy and correlate it with the clinical course. 4. to gain knowledge from these analyses and the clinical course concerning the pathogenesis and the point of attack for possible therapies in chronic reactive arthritis. 5. to compare cytokine-profiles of CD4- and CD8-positive T-cells from patients treated with infliximab to those treated with etanercept.
Timeline
- Start
- 2003-01
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Infliximab | Monoclonal antibody | 1 mg/kg | — |
| Subject | Infliximab | Monoclonal antibody | 5 mg/kg | — |
| Subject | Infliximab | Monoclonal antibody | 10 mg/kg | — |
| Subject | Leflunomide | Small molecule | — | — |
| Subject | Methotrexate | Small molecule | — | — |
| Subject | Sulfasalazine | Small molecule | — | — |
| Subject | interferon gamma | Protein / enzyme biologic | 50 ug | Subcutaneous |
| Subject | interferon gamma | Protein / enzyme biologic | 100 ug | Subcutaneous |
| Subject | interferon gamma | Protein / enzyme biologic | 150 ug | Subcutaneous |